All Stories

  1. Fully-automated sleep staging for Parkinson’s disease and isolated REM sleep behavior disorder
  2. Brain-first and body-first subtypes of Lewy body disease
  3. Cardiac sympathetic degeneration informs the duration of the prodromal stage of body-first Lewy body disease
  4. Exploring MAPT-containing H1 and H2 haplotypes in Parkinson’s disease across diverse populations
  5. ActiTect: a generalizable machine learning pipeline for REM sleep behavior disorder screening through standardized actigraphy
  6. Atlas of Brain Glucose Metabolism Using Deuterium Metabolic Imaging at 3 T
  7. Co‐ and Multi‐Pathologies in Parkinson's Disease: An International Parkinson and Movement Disorder Society Scientific Issues Committee Review
  8. ODIN Biobank: a Danish cohort for dementia research- cohort profile
  9. Genome-wide association study of copy number variations in Parkinson’s disease
  10. Impaired sleep microarchitecture is associated with locus coeruleus degeneration in Parkinson’s disease
  11. Differential Progression of Neuroinflammation in Patients with Isolated Rapid‐Eye‐Movement Sleep Behavior Disorder
  12. Patients with symmetric Parkinson’s disease do poorly with subthalamic stimulation
  13. Robust Immunohistochemical Detection of α-Synuclein, Tau, and β-Amyloid in Human Brain Tissue Archived for up to 78 Years
  14. Spinal cord stimulation therapy for gait impairment in Parkinson’s disease: a double-blinded, randomised feasibility trial with an open extension
  15. Hemispheric lateralization of dopamine transporter binding in Parkinson's disease
  16. Depression preceding and following the diagnosis of Parkinson’s disease and Lewy body dementia
  17. Myocardial sympathetic distal axon loss in subjects with Lewy pathology: an artificial intelligence‐based histopathological analysis
  18. Idiopathic polyneuropathy with neurogenic autonomic failure – an early manifestation of Lewy body disease? a case report
  19. Estrogen-related receptor gene expression associates with sex differences in cortical atrophy in isolated REM sleep behavior disorder
  20. Inter-relationship of the age of onset to the concept of brain-first versus body-first Parkinson's disease
  21. Myocardial sympathetic distal axon loss in subjects with Lewy pathology in three autopsy cohorts
  22. Trusting Your Gut When it Comes to the Origin of Parkinson's Disease
  23. Distinct brain atrophy progression subtypes underlie phenoconversion in isolated REM sleep behaviour disorder
  24. Cholinergic patterns correlate with dopamine medication ON freezing of gait in Parkinson’s disease
  25. Impaired sleep microarchitecture is associated with locus coeruleus degeneration in Parkinson’s disease
  26. Comparison of Deuterium Metabolic Imaging with FDG PET in Alzheimer Disease
  27. Sympathetic and parasympathetic subtypes of body-first Lewy body disease observed in postmortem tissue from prediagnostic individuals
  28. The Gut‐Brain Axis in Parkinson disease: Emerging Concepts and Therapeutic Implications
  29. Impact of norepinephrine versus phenylephrine on brain circulation, organ blood flow and tissue oxygenation in anaesthetised patients with brain tumours: study protocol for a randomised controlled trial
  30. Bradykinesia and postural instability in a model of prodromal synucleinopathy with α-synuclein aggregation initiated in the gigantocellular nuclei
  31. Nigral Neuroinflammation and Dopaminergic Neurons in Parkinson's Disease and Atypical Parkinsonisms
  32. Validation of a data-driven motion-compensated PET brain image reconstruction algorithm in clinical patients using four radiotracers
  33. Non-motor asymmetry and dopamine degeneration in Parkinson’s disease
  34. Cuneus atrophy and Parkinsonian phenoconversion in cognitively unimpaired patients with isolated REM sleep behavior disorder
  35. Cortical hypometabolism in Parkinson’s disease is linked to cholinergic basal forebrain atrophy
  36. Cholinergic dysfunction in isolated rapid eye movement sleep behaviour disorder links to impending phenoconversion
  37. Correlation between dopaminergic and metabolic asymmetry in Lewy body disease – A dual-imaging study
  38. Approaches to Early Parkinson’s Disease Subtyping
  39. Jellinger K, “Parkinson’s Disease and Dementia with Lewy Bodies: One and the Same”
  40. Predictors of short-term anxiety outcome in subthalamic stimulation for Parkinson’s disease
  41. Parkinson’s Disease and Dementia with Lewy Bodies: One and the Same
  42. The Body, the Brain, the Environment, and Parkinson’s Disease
  43. Functional and 123I-MIBG scintigraphy assessment of cardiac adrenergic dysfunction in diabetes
  44. Microglial Activation and Progression of Nigrostriatal Dysfunction in Isolated REM Sleep Behavior Disorder
  45. Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson’s disease
  46. Cholinergic changes in Lewy body disease: implications for presentation, progression and subtypes
  47. Brain-first vs. body-first Parkinson's disease: An update on recent evidence
  48. Impaired cholinergic integrity of the colon and pancreas in dementia with Lewy bodies
  49. STING activation counters glioblastoma by vascular alteration and immune surveillance
  50. Progression of brain cholinergic dysfunction in patients with isolated rapid eye movement sleep behavior disorder
  51. Severe cholinergic terminal loss in newly diagnosed dementia with Lewy bodies
  52. Sertraline treatment influences [18F]FE-PE2I PET imaging for Parkinsonism
  53. Dopaminergic Dysfunction Is More Symmetric in Dementia with Lewy Bodies Compared to Parkinson’s Disease
  54. The heterogeneity of Parkinson’s disease
  55. The brain-first vs. body-first model of Parkinson’s disease with comparison to alternative models
  56. Distribution of cholinergic nerve terminals in the aged human brain measured with [18F]FEOBV PET and its correlation with histological data
  57. Synaptic Density and Glucose Consumption in Patients with Lewy Body Diseases : An [ 11 C ] UCB‐J ...
  58. Thyroid [123I]MIBG uptake in Parkinson’s disease and diabetes mellitus
  59. Mitochondrial function-associated genes underlie cortical atrophy in prodromal synucleinopathies
  60. Cholinergic Imaging and Dementia
  61. Disruption of Sleep Microarchitecture Is a Sensitive and Early Marker of Parkinson’s Disease
  62. Mapping Cholinergic Synaptic Loss in Parkinson’s Disease: An [18F]FEOBV PET Case-Control Study
  63. RBDtector: an open-source software to detect REM sleep without atonia according to visual scoring criteria
  64. Revisiting the Dual-Hit Hypothesis: Insights from Postmortem Studies in Parkinson's Disease
  65. [18F]FEOBV positron emission tomography may not be a suitable method to measure parasympathetic denervation in patients with Parkinson's disease
  66. Healthy brain aging assessed with [18F]FDG and [11C]UCB-J PET
  67. Imaging progressive peripheral and central dysfunction in isolated REM sleep behaviour disorder after 3 years of follow-up
  68. Spinal cord stimulation therapy for patients with Parkinson’s disease and gait problems (STEP-PD): study protocol for an exploratory, double-blind, randomised, placebo-controlled feasibility trial
  69. Impact of aging on animal models of Parkinson's disease
  70. Intestinal Transit in Early Moderate Parkinson’s Disease Correlates with Probable RBD: Subclinical Esophageal Dysmotility Does Not Correlate
  71. Alpha-Synuclein Strain Variability in Body-First and Brain-First Synucleinopathies
  72. Brain atrophy in prodromal synucleinopathy is shaped by structural connectivity and gene expression
  73. In vivo vesicular acetylcholine transporter density in human peripheral organs: an [18F]FEOBV PET/CT study
  74. Cholinergic system changes in Parkinson's disease: emerging therapeutic approaches
  75. Passive Immunization in Alpha-Synuclein Preclinical Animal Models
  76. Asymmetric amyloid deposition in preclinical Alzheimer’s disease: A PET study
  77. Brain atrophy in prodromal synucleinopathy is shaped by structural connectivity and gene expression
  78. Neuropathological evidence of body-first vs. brain-first Lewy body disease
  79. Long-term Risk of Parkinson Disease Following Influenza and Other Infections
  80. Asymmetric Dopaminergic Dysfunction in Brain-First versus Body-First Parkinson’s Disease Subtypes
  81. Constipation is Associated with Development of Cognitive Impairment in de novo Parkinson’s Disease: A Longitudinal Analysis of Two International Cohorts
  82. Gastric Emptying Time and Volume of the Small Intestine as Objective Markers in Patients With Symptoms of Diabetic Enteropathy
  83. Radionuclide imaging of the gut-brain axis in Parkinson’s disease
  84. Cortical Activity During an Attack of Ménière's Disease—A Case Report
  85. Regional locus coeruleus degeneration is uncoupled from noradrenergic terminal loss in Parkinson’s disease
  86. Vagus Nerve Cross-Sectional Area in Patients With Parkinson's Disease—An Ultrasound Case-Control Study
  87. Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease
  88. Fasting gallbladder volume is increased in patients with Parkinson's disease
  89. Preserved noradrenergic function in Parkinson's disease patients with rest tremor
  90. Reduced Synaptic Density in Patients with Lewy Body Dementia: An [ 11 C ] UCB‐J PET Imaging Study
  91. Ageing promotes pathological alpha-synuclein propagation and autonomic dysfunction in wild-type rats
  92. Prodromal Parkinson disease subtypes — key to understanding heterogeneity
  93. Impaired cerebral microcirculation in isolated REM sleep behaviour disorder
  94. The α-Synuclein Origin and Connectome Model (SOC Model) of Parkinson’s Disease: Explaining Motor Asymmetry, Non-Motor Phenotypes, and Cognitive Decline
  95. Asymmetric Distribution of Dopamine Transporters in Premorbid Corticobasal Syndrome—A Case Report
  96. Assessment of Gastrointestinal Autonomic Dysfunction: Present and Future Perspectives
  97. Monocyte markers correlate with immune and neuronal brain changes in REM sleep behavior disorder
  98. The Logic and Pitfalls of Parkinson's as Brain‐ Versus Body‐First Subtypes
  99. Microsleep disturbances are associated with noradrenergic dysfunction in Parkinson’s disease
  100. Cognitive impairment in Parkinson's disease is associated with Default Mode Network subsystem connectivity and cerebrospinal fluid Aβ
  101. Gastrointestinal Dysfunction in Parkinson’s Disease
  102. Assessing autonomic dysfunction with functional imaging in Parkinson's disease
  103. Cortical cholinergic dysfunction correlates with microglial activation in the substantia innominata in REM sleep behavior disorder
  104. Abstract
  105. Brain-first versus body-first Parkinson’s disease: a multimodal imaging case-control study
  106. Absent 18F-FDG Uptake in the Brain—Unsuspected Brain Death
  107. Skin Temperature in Parkinson’s Disease Measured by Infrared Thermography
  108. Colonic motility in patients with type 1 diabetes and gastrointestinal symptoms
  109. Altered sensorimotor cortex noradrenergic function in idiopathic REM sleep behaviour disorder – A PET study
  110. A Screening-Based Method for Identifying Patients with REM Sleep Behaviour Disorder in a Danish Community Setting
  111. Imaging dopamine function and microglia in asymptomatic LRRK2 mutation carriers
  112. Applied strategy in the Iowa Gambling Task: Comparison of individuals with Parkinson’s disease to healthy controls
  113. Normative values for gastric motility assessed with the 3D‐transit electromagnetic tracking system
  114. PET Visualized Stimulation of the Vestibular Organ in Menière's Disease
  115. Tau Tangles in Parkinson’s Disease: A 2-Year Follow-Up Flortaucipir PET Study
  116. Cholinergic denervation in patients with idiopathic rapid eye movement sleep behaviour disorder
  117. In vivo positron emission tomography imaging of decreased parasympathetic innervation in the gut of vagotomized patients
  118. Brain-First versus Gut-First Parkinson’s Disease: A Hypothesis
  119. Enteric cholinergic neuropathy in patients with diabetes: Non‐invasive assessment with positron emission tomography
  120. Normative values for region‐specific colonic and gastrointestinal transit times in 111 healthy volunteers using the 3D‐Transit electromagnet tracking system: Influence of age, gender, and body mass index
  121. Positron emission tomography visualized stimulation of the vestibular organ is localized in Heschl's gyrus
  122. 18F-Fluciclovine PET/CT in Suspected Residual or Recurrent High-Grade Glioma
  123. Engineered antibodies: new possibilities for brain PET?
  124. Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats
  125. 18F-FACBC PET/MRI in Diagnostic Assessment and Neurosurgery of Gliomas
  126. Cardiac 11C-Donepezil Binding Increases With Age in Healthy Humans: Potentially Signifying Sigma-1 Receptor Upregulation
  127. The Gut and Parkinson’s Disease: Hype or Hope?
  128. Imaging the Autonomic Nervous System in Parkinson’s Disease
  129. Evaluation of Active Brown Adipose Tissue by the Use of Hyperpolarized [1-13C]Pyruvate MRI in Mice
  130. Does inflammation precede tau aggregation in early Alzheimer's disease? A PET study
  131. Objective intestinal function in patients with idiopathic REM sleep behavior disorder
  132. Is constipation in Parkinson's disease caused by gut or brain pathology?
  133. The Effect of 40-Hz Light Therapy on Amyloid Load in Patients with Prodromal and Clinical Alzheimer’s Disease
  134. Extrastriatal monoaminergic dysfunction and enhanced microglial activation in idiopathic rapid eye movement sleep behaviour disorder
  135. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study
  136. Preclinical evaluation of potential infection-imaging probe [68 Ga]Ga-DOTA-K-A9 in sterile and infectious inflammation
  137. Gastrointestinal transit time and heart rate variability in patients with mild acquired brain injury
  138. Gastric emptying in Parkinson's disease – A mini-review
  139. Decreased noradrenaline transporter density in the motor cortex of Parkinson's disease patients
  140. F26. Automated chin EMG analysis for quantification of REM sleep without atonia
  141. Observations on muscle activity in REM sleep behavior disorder assessed with a semi-automated scoring algorithm
  142. Molecular Imaging of the Noradrenergic System in Idiopathic Parkinson's Disease
  143. Evaluation of the noradrenergic system in Parkinson’s disease: an 11C-MeNER PET and neuromelanin MRI study
  144. Multimodal 18 F-Fluciclovine PET/MRI and Ultrasound-Guided Neurosurgery of an Anaplastic Oligodendroglioma
  145. Tonsillectomy and risk of Parkinson's disease: A danish nationwide population-based cohort study
  146. MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([18F]-AV-1451) Binding
  147. Pancreatic Polypeptide in Parkinson’s Disease: A Potential Marker of Parasympathetic Denervation
  148. Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study
  149. Noradrenergic Deficits in Parkinson Disease Imaged with 11C-MeNER
  150. How does parkinson's disease begin? Perspectives on neuroanatomical pathways, prions, and histology
  151. Gastrointestinal Transit Time in Parkinson’s Disease Using a Magnetic Tracking System
  152. Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer’s disease
  153. Objective Colonic Dysfunction is Far more Prevalent than Subjective Constipation in Parkinson’s Disease: A Colon Transit and Volume Study
  154. Preventing Parkinson disease by vagotomy
  155. Imaging Parkinson’s disease below the neck
  156. Reply to the letter to the Editor: Comment to Barichella and colleagues
  157. In Vivo cortical tau in Parkinson's disease using 18F-AV-1451 positron emission tomography
  158. Functional image-guided dose escalation in gliomas using of state-of-the-art photon vs. proton therapy
  159. Decreased intestinal acetylcholinesterase in early Parkinson disease
  160. Kinetic Modelling of Infection Tracers [18F]FDG, [68Ga]Ga-Citrate, [11C]Methionine, and [11C]Donepezil in a Porcine Osteomyelitis Model
  161. Constipation in parkinson's disease: Subjective symptoms, objective markers, and new perspectives
  162. Cholinergic PET imaging in infections and inflammation using 11C-donepezil and 18F-FEOBV
  163. Appendectomy and risk of Parkinson's disease: A nationwide cohort study with more than 10 years of follow-up
  164. Constipation and risk of Parkinson’s disease: A Danish population-based cohort study
  165. Vagotomy and subsequent development of diabetes – A nested case–control study
  166. A dual tracer 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT pilot study for detection of cardiac sarcoidosis
  167. In vivoimaging of neuromelanin in Parkinson’s disease using18F-AV-1451 PET
  168. Imaging Systemic Dysfunction in Parkinson’s Disease
  169. Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients
  170. Sex differences of human cortical blood flow and energy metabolism
  171. Does vagotomy reduce the risk of Parkinson's disease: The authors reply
  172. Accuracy of 18F-FDG PET-CT in triaging lung cancer patients with suspected brain metastases for MRI
  173. EANM’15
  174. Reply
  175. Pseudoprogression after proton radiotherapy for pediatric low grade glioma
  176. Spatial distribution of malignant tissue in gliomas: correlations of 11C-L-methionine positron emission tomography and perfusion- and diffusion-weighted magnetic resonance imaging
  177. Molecular imaging of cholinergic processes in prostate cancer using 11C-donepezil and 18F-FEOBV
  178. Clinical correlates of raphe serotonergic dysfunction in early Parkinson’s disease
  179. Vagotomy and subsequent risk of Parkinson's disease
  180. Olfactory function in Parkinson's Disease - effects of training
  181. Salivary Acetylcholinesterase Activity Is Increased in Parkinson’s Disease: A Potential Marker of Parasympathetic Dysfunction
  182. Imaging the parasympathetic nervous system in Parkinson's disease
  183. In Vivo Imaging of Human Acetylcholinesterase Density in Peripheral Organs Using 11C-Donepezil: Dosimetry, Biodistribution, and Kinetic Analyses
  184. Combined DaT imaging and olfactory testing for differentiating parkinsonian disorders
  185. False-Positive 123I-FP-CIT Scintigraphy and Suggested Dopamine Transporter Upregulation Due to Chronic Modafinil Treatment
  186. Brain Energy Metabolism and Blood Flow Differences in Healthy Aging
  187. Cerebral oxygen metabolism in patients with early Parkinson's disease
  188. Clinical heterogeneity in Parkinson’s disease revisited: a latent profile analysis
  189. Glucose metabolism in small subcortical structures in Parkinson’s disease
  190. Odor identification deficits identify Parkinson's disease patients with poor cognitive performance
  191. The Parkinsonian Personality and Concomitant Depression
  192. Molecular Imaging and the Neuropathologies of Parkinson’s Disease
  193. Variable ATP Yields and Uncoupling of Oxygen Consumption in Human Brain
  194. Cortical hypometabolism and hypoperfusion in Parkinson’s disease is extensive: probably even at early disease stages
  195. Partial volume correction using cortical surfaces
  196. Age-dependent decline of steady state dopamine storage capacity of human brain: An FDOPA PET study
  197. A deformation-based morphometry study of patients with early-stage Parkinson’s disease
  198. Subcortical elevation of metabolism in Parkinson's disease — A critical reappraisal in the context of global mean normalization
  199. Data-driven intensity normalization of PET group comparison studies is superior to global mean normalization
  200. Artefactual subcortical hyperperfusion in PET studies normalized to global mean: Lessons from Parkinson’s disease
  201. Low Cerebral Oxygen Consumption and Blood Flow in Patients With Cirrhosis and an Acute Episode of Hepatic Encephalopathy
  202. Improvement of brain tissue oxygenation by inhalation of carbogen
  203. Effect of memantine on CBF and CMRO2in patients with early Parkinson’s disease
  204. Normalization in PET group comparison studies—The importance of a valid reference region
  205. Fluorodopa F 18 Positron Emission Tomography and the Progression of Parkinson Disease